<code id='1BEE5CA2AE'></code><style id='1BEE5CA2AE'></style>
    • <acronym id='1BEE5CA2AE'></acronym>
      <center id='1BEE5CA2AE'><center id='1BEE5CA2AE'><tfoot id='1BEE5CA2AE'></tfoot></center><abbr id='1BEE5CA2AE'><dir id='1BEE5CA2AE'><tfoot id='1BEE5CA2AE'></tfoot><noframes id='1BEE5CA2AE'>

    • <optgroup id='1BEE5CA2AE'><strike id='1BEE5CA2AE'><sup id='1BEE5CA2AE'></sup></strike><code id='1BEE5CA2AE'></code></optgroup>
        1. <b id='1BEE5CA2AE'><label id='1BEE5CA2AE'><select id='1BEE5CA2AE'><dt id='1BEE5CA2AE'><span id='1BEE5CA2AE'></span></dt></select></label></b><u id='1BEE5CA2AE'></u>
          <i id='1BEE5CA2AE'><strike id='1BEE5CA2AE'><tt id='1BEE5CA2AE'><pre id='1BEE5CA2AE'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:3
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          As pharma fights Medicare drug negotiation, hospitals, docs silent
          As pharma fights Medicare drug negotiation, hospitals, docs silent

          AdobeThepharmaceuticalindustryhasbeenupinarmsoverMedicare’sfirstlistof10prescriptiondrugsthatwillbes

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          How to use technology to prevent future drug shortages

          TherehasbeenapersistentshortageoftheADHDdrugAdderall.JennyKane/APMyfirstexposuretopharmaceuticalshor